Brief: Zai Lab And Argenx Announce Approval Of Efgartigimod Alfa Injection For Generalized Myasthenia Gravis In China
16/07/2024 05:16
July 16 (Reuters) - Zai Lab Ltd 9688.HK :
* ZAI LAB AND ARGENX ANNOUNCE APPROVAL OF EFGARTIGIMOD ALFA
INJECTION (SUBCUTANEOUS INJECTION) FOR GENERALIZED MYASTHENIA
GRAVIS IN CHINA
Source text for Eikon: ID:nBw7myLrha
Further company coverage: 9688.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles